Lundbeckfonden
Lundbeckfonden provides financial support to scientific research and life science companies.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Lundbeckfonden Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Facebook
Linkedin
Crunchbase
Metrics
1,269,425Website Global Rank
23,038Website Monthly Traffic
Twitter Followers
Description
Lundbeckfonden provides financial support to scientific research and life science companies.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 4/2012 | AlloCure | Series B | 25M |
| 3/2017 | Spero Therapeutics | Series C | 51.7M |
| 10/2013 | Cydan | Venture Round | 10M |
| 1/2017 | ENTEROME | Series D | 33.4M |
| 7/2012 | Akamis Bio | Series B | 34.1M |
| 4/2010 | Asante Solutions | Series B | - |
| 10/2016 | BONESUPPORT | Venture Round | 36.1M |
| 6/2012 | BONESUPPORT | Venture Round | 10M |
| 3/2012 | ENTEROME | Series A | 0 |
| 12/2020 | Reneo Pharmaceuticals | Series B | 0 |
| 7/2017 | Trevi Therapeutics | Series C | 30M |
| 1/2019 | Trevi Therapeutics | Series C | 10M |
| 9/2021 | LEXEO Therapeutics | Series B | 0 |
| 12/2017 | Aura Biosciences | Series C | 0 |
| 3/2014 | scPharmaceuticals | Series A | 16M |
| 2/2012 | Celladon | Venture Round | 43M |
| 1/2011 | Nexstim | Venture Round | 0 |
| 6/2019 | SANIFIT | Series D | 0 |
| 1/2018 | ENTEROME | Debt Financing | - |
| 5/2014 | ENTEROME | Series B | 15.3M |
| 4/2016 | ENTEROME | Series C | 16.4M |
| 1/2021 | LEXEO Therapeutics | Series A | 0 |
| 4/2013 | DYSIS Medical | Venture Round | 11.3M |
| 7/2018 | DYSIS Medical | Venture Round | 23.9M |
| 5/2020 | Amplyx Pharmaceuticals | Series C | 0 |
| 3/2019 | SNIPR Biome | Series A | 50M |
| 9/2015 | SANIFIT | Series C | 0 |
| 2/2016 | Spero Therapeutics | Series B | 30M |
| 10/2017 | Cydan | Venture Round | 34M |
| 1/2017 | scPharmaceuticals | Series B | 45.6M |
| 7/2014 | Atox Bio | Series E | 23M |
| 6/2015 | Spero Therapeutics | Series A | 0 |
| 8/2018 | Trevi Therapeutics | Series C | 10.5M |
| 11/2010 | Syntaxin | Series C | 29M |
| 5/2015 | Akamis Bio | Series C | 38.8M |
| 12/2013 | VHSquared | Series A | - |
| 9/2015 | Biom&s;Up | Series C | 35.3M |
| 2/2014 | Thesan Pharmaceuticals | Series B | 49M |
| 7/2016 | Vtesse | Series A | 17M |
| 9/2013 | Acacia Pharma | Series B | 23.5M |
| 12/2017 | Atox Bio | Series F | 0 |
| 5/2020 | IO Biotech | Debt Financing | 0 |
| 1/2011 | DBV Technologies | Series C | 25.5M |
| 5/2023 | VarmX | Series B | 0 |
| 1/2016 | IO Biotech | Series A | 11.8M |
| 3/2019 | Imara | Series B | 0 |
| 5/2019 | Reneo Pharmaceuticals | Series A | 50M |
| 4/2016 | Imara | Series A | 31M |
| 12/2012 | River Vision Development | Series A | 17M |
| 3/2021 | Aura Biosciences | Venture Round | 0 |
| 6/2018 | Iconic Therapeutics | Venture Round | 0 |
| 4/2014 | Iconic Therapeutics | Series B | 20M |
| 1/2016 | Iconic Therapeutics | Series C | 40M |
| 8/2016 | Iconic Therapeutics | Series C | 10M |
| 11/2014 | Ziarco | Series B | 33M |
| 1/2015 | Vtesse | Series A | 25M |
| 8/2017 | Amplyx Pharmaceuticals | Series C | 0 |
| 1/2019 | Tiburio Therapeutics | Series A | 31M |
| 3/2011 | Acacia Pharma | Series A | 10M |
| 7/2020 | VarmX | Series B | 36.3M |
| 9/2021 | LEXEO Therapeutics | Series B | 0 |
| 3/2021 | Aura Biosciences | Venture Round | 0 |
| 1/2021 | LEXEO Therapeutics | Series A | 0 |
| 12/2020 | Reneo Pharmaceuticals | Series B | 0 |
| 7/2020 | VarmX | Series B | 0 |
| 5/2020 | Amplyx Pharmaceuticals | Series C | 0 |
| 5/2020 | IO Biotech | Debt Financing | 0 |
| 6/2019 | SANIFIT | Series D | 0 |
| 5/2019 | Reneo Pharmaceuticals | Series A | 0 |
| 3/2019 | Imara | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
